Press Releases Year: - Any -202320222021202020192018201720162015201420132012201120102009 Items per page 102550 July 6, 2009 Summary ToggleMerrimack Pharmaceuticals Initiates Enrollment in a Phase 1/2 Study of MM-111, a bispecific antibody to ErbB2/3 Merrimack Pharmaceuticals’ second of five oncology pipeline candidates, MM-111, has entered clinical development. June 25, 2009 Summary Toggle'Science Signaling' to Publish Paper on Therapeutically Targeting ErbB3 to Treat Overexpressed or Mutated Oncogenes April 16, 2009 Summary ToggleMerrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the Annual Meeting of the American Association for Cancer Research Pagination First page First Previous page Previous … Page 26 Page 27 Page 28 Current page 29
